- Strategic collaboration announced for bispecific programs: Novartis to receive ex-U.S. rights to XmAb®14045 and XmAb®13676, Xencor to retain U.S. commercial rights -- XmAb®18087 and XmAb®20717 named as two XmAb® bispecific oncology candidates for treatment of neuroendocrine tumors and multiple cancers, respectively; on track to have four bispecific programs in clinic in 2017 -

- Novartis to receive ex-U.S. rights to XmAb14045 and XmAb13676- Xencor retains all U.S. rights to XmAb14045 and XmAb13676- Collaboration also includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies

MONROVIA, Calif. , June 14, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company will host an

- 75% of high IgE subjects had reduction of free IgE below limit of detection following a single intravenous infusion across all dose levels -- Generally well tolerated as an intravenous infusion with transient, asymptomatic thrombocytopenia at doses ≥2.0 mg/kg -

MONROVIA, Calif. , May 17, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , president

MONROVIA, Calif. , May 2, 2016 /PRNewswire/ --  Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the first

MONROVIA, Calif. , April 25, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter

MONROVIA, Calif. , March 7, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the fourth

Advancing XmAb5871 in two indications with high unmet need and strong rationale for B-cell inhibitionNovel trial design for SLE intended to detect statistically significant treatment effect after 6 months of therapy

MONROVIA, Calif. , March 2, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , president